Senior Research Scientist
Stephanie joined the HTS group in April 2016. She is responsible for developing and running high throughput screens, including ELISAs and various cellular phenotypic screens. Previously she performed cell-based assays as part of the Structural Genomic Consortium. She obtained her PhD from the University of North Carolina, Chapel Hill.
Small molecule screen employing patient-derived iPSC hepatocytes identifies LRRK2 as a novel therapeutic target for Alpha1 Antitrypsin Deficiency
Kent D. et al, (2022)
CHK1 inhibition exacerbates replication stress induced by IGF blockade.
Wu X. et al, (2022), Oncogene, 41, 476 - 488
The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers.
Lumley SF. et al, (2021), Clin Infect Dis, 73, e699 - e709
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.
Lumley SF. et al, (2021), N Engl J Med, 384, 533 - 540
The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification.
Wells CI. et al, (2021), Int J Mol Sci, 22